Drugs / Loestrin 1.5/30
last change Jan 2016 re-read 2 minutes ago

Loestrin 1.5/30

Investigated by
GlaxoSmithKline · ViiV Healthcare

Trials 1 · a red edge is where a trial was stopped

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02480881 Jul 2015 → Jan 2016 HIV infectious disease ViiV Healthcare Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Loestrin 1.5/30 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02480881
Route Oral “Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth.” NCT02480881